一名接受杜匹单抗治疗的患者出现严重的高嗜酸性粒细胞增多症并转为使用麦泊利单抗：多学科管理的重要性。病例报告和文献综述

Drugs in Context Pub Date : 2024-05-22 DOI:10.7573/dic.2024-3-5

Sara Munari, Giulia Ciotti, Walter Cestaro, Lorenzo Corsi, S. Tonin, Andrea Ballarin, Ariel Floriani, Cristina Dartora, Annamaria Bosi, Matteo Tacconi, Francesco Gialdini, Michele Gottardi, Francesco Menzella

{"title":"一名接受杜匹单抗治疗的患者出现严重的高嗜酸性粒细胞增多症并转为使用麦泊利单抗：多学科管理的重要性。病例报告和文献综述","authors":"Sara Munari, Giulia Ciotti, Walter Cestaro, Lorenzo Corsi, S. Tonin, Andrea Ballarin, Ariel Floriani, Cristina Dartora, Annamaria Bosi, Matteo Tacconi, Francesco Gialdini, Michele Gottardi, Francesco Menzella","doi":"10.7573/dic.2024-3-5","DOIUrl":null,"url":null,"abstract":"Type 2 inflammation is a heterogeneous condition due to the complex activation of different immunological pathways. Rapid progress in research to evaluate the efficacy of biologics for chronic rhinosinusitis with nasal polyps and asthma has led to the availability of effective therapeutic options. These drugs are safe, but temporary iatrogenic hypereosinophilia may sometimes be associated with clinical symptoms or organ damage. Here, we describe a case of severe hypereosinophilia in a patient with chronic rhinosinusitis with nasal polyps and asthma treated with dupilumab and a subsequent therapeutic shift to mepolizumab that led to","PeriodicalId":502654,"journal":{"name":"Drugs in Context","volume":"56 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review\",\"authors\":\"Sara Munari, Giulia Ciotti, Walter Cestaro, Lorenzo Corsi, S. Tonin, Andrea Ballarin, Ariel Floriani, Cristina Dartora, Annamaria Bosi, Matteo Tacconi, Francesco Gialdini, Michele Gottardi, Francesco Menzella\",\"doi\":\"10.7573/dic.2024-3-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Type 2 inflammation is a heterogeneous condition due to the complex activation of different immunological pathways. Rapid progress in research to evaluate the efficacy of biologics for chronic rhinosinusitis with nasal polyps and asthma has led to the availability of effective therapeutic options. These drugs are safe, but temporary iatrogenic hypereosinophilia may sometimes be associated with clinical symptoms or organ damage. Here, we describe a case of severe hypereosinophilia in a patient with chronic rhinosinusitis with nasal polyps and asthma treated with dupilumab and a subsequent therapeutic shift to mepolizumab that led to\",\"PeriodicalId\":502654,\"journal\":{\"name\":\"Drugs in Context\",\"volume\":\"56 12\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in Context\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7573/dic.2024-3-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2024-3-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

由于不同免疫途径的复杂激活，2 型炎症是一种异质性疾病。在评估生物制剂对慢性鼻炎伴鼻息肉和哮喘的疗效方面，研究取得了快速进展，从而提供了有效的治疗方案。这些药物是安全的，但暂时性的先天性嗜酸性粒细胞过多症有时可能与临床症状或器官损伤有关。在此，我们描述了一例使用杜必鲁单抗治疗的慢性鼻窦炎伴鼻息肉和哮喘患者的严重嗜酸性粒细胞增多症，以及随后转用甲泼尼单抗治疗后导致的

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review

Type 2 inflammation is a heterogeneous condition due to the complex activation of different immunological pathways. Rapid progress in research to evaluate the efficacy of biologics for chronic rhinosinusitis with nasal polyps and asthma has led to the availability of effective therapeutic options. These drugs are safe, but temporary iatrogenic hypereosinophilia may sometimes be associated with clinical symptoms or organ damage. Here, we describe a case of severe hypereosinophilia in a patient with chronic rhinosinusitis with nasal polyps and asthma treated with dupilumab and a subsequent therapeutic shift to mepolizumab that led to

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs in Context

自引率

0.00%

发文量